Du Jiejun相关文献与解析，生知库 | 链接生命科学的每一步

日期影响因子

Safety, Tolerability, and Immunogenicity of Revaccination With mRNA-1345, an mRNA Vaccine Against Respiratory Syncytial Virus, Administered 12 Months Following a Primary Dose in Adults Aged ≥50 Years

在≥50岁的成年人中，接种mRNA-1345（一种针对呼吸道合胞病毒的mRNA疫苗）12个月后再次接种的安全性、耐受性和免疫原性

期刊:Clinical Infectious Diseases

影响因子:7.3

doi:10.1093/cid/ciaf515

Goswami, Jaya; Cardona, Jose F; Caso, Jorge; Hsu, Denise C; Simorellis, Alana K; Wilson, Lauren; Dhar, Rakesh; Wang, Xiaowei; Kapoor, Archana; Collins, Avi; Righi, Vinicius; Lan, Lan; Du, Jiejun; Zhou, Honghong; Stoszek, Sonia K; Shaw, Christine A; Reuter, Caroline; Wilson, Eleanor; Das, Rituparna

免疫/内分泌

发表日期：2026

文献求助收藏

Immune correlates analysis of mRNA-1345 RSV vaccine efficacy clinical trial.

mRNA-1345 RSV疫苗疗效临床试验的免疫相关性分析

期刊:Nature Communications

影响因子:15.7

doi:10.1038/s41467-025-61153-x

Ma Chong, Du Jiejun, Lan Lan, Kapoor Archana, Marc Gonzalo Perez, Jimenez Gilberto, Duncan Christopher J A, Le Cam Nancy, Lin Nina, Priddy Frances, Garg Sanjay, Stoszek Sonia K, Shaw Christine A, Goswami Jaya, Wilson Eleanor, Das Rituparna, Zhou Honghong, Zheng Lingyi

免疫/内分泌

发表日期：2025

文献求助收藏

Correction to: Virologic Outcomes with Molnupiravir in Nonhospitalized Adult Patients with COVID-19 from the Randomized, Placebo-Controlled MOVe-OUT Trial

更正：来自随机、安慰剂对照 MOVe-OUT 试验的莫努匹拉韦治疗非住院 COVID-19 成年患者的病毒学结果

期刊:Infectious Diseases and Therapy

影响因子:5.3

doi:10.1007/s40121-024-00947-w

Strizki, Julie M; Grobler, Jay A; Murgolo, Nicholas; Fridman, Arthur; Johnson, Matthew G; Du, Jiejun; Carmelitano, Patricia; Brown, Michelle L; Paschke, Amanda; De Anda, Carisa

发表日期：2024

文献求助收藏

Humoral Immunogenicity of mRNA-1345 RSV Vaccine in Older Adults

mRNA-1345 RSV疫苗在老年人群中的体液免疫原性

期刊:Journal of Infectious Diseases

影响因子:4.5

doi:10.1093/infdis/jiae316

Goswami, Jaya; Baqui, Abdullah H; Doreski, Pablo A; Perez Marc, Gonzalo; Jimenez, Gilberto; Ahmed, Salahuddin; Zaman, Khalequz; Duncan, Christopher J A; Ujiie, Mugen; Rämet, Mika; Pérez-Breva, Lina; Lan, Lan; Du, Jiejun; Kapoor, Archana; Mehta, Shraddah; Tomassini, Joanne E; Huang, Wenmei; Zhou, Honghong; Stoszek, Sonia K; Priddy, Frances; Lin, Nina; Le Cam, Nancy; Shaw, Christine A; Slobod, Karen; Wilson, Eleanor; Miller, Jacqueline M; Das, Rituparna

免疫/内分泌

发表日期：2024

文献求助收藏

Impact of Molnupiravir Treatment on Patient-Reported COVID-19 Symptoms in the Phase 3 MOVe-OUT Trial: A Randomized, Placebo-Controlled Trial

在 MOVe-OUT 三期试验中，莫努匹拉韦治疗对患者报告的 COVID-19 症状的影响：一项随机、安慰剂对照试验

期刊:Clinical Infectious Diseases

影响因子:7.3

doi:10.1093/cid/ciad409

Guan, Yanfen; Puenpatom, Amy; Johnson, Matthew G; Zhang, Ying; Zhao, Yujie; Surber, Joseph; Weinberg, Aaron; Brotons, Carlos; Kozlov, Roman; Lopez, Rudy; Coetzee, Kathleen; Santiaguel, Joel; Du, Jiejun; Williams-Diaz, Angela; Brown, Michelle; Paschke, Amanda; De Anda, Carisa; Norquist, Josephine M

发表日期：2023

文献求助收藏

Virologic Outcomes with Molnupiravir in Non-hospitalized Adult Patients with COVID-19 from the Randomized, Placebo-Controlled MOVe-OUT Trial

来自随机、安慰剂对照的 MOVe-OUT 试验中，莫努匹拉韦治疗非住院 COVID-19 成年患者的病毒学结果

期刊:Infectious Diseases and Therapy

影响因子:5.3

doi:10.1007/s40121-023-00891-1

Strizki, Julie M; Grobler, Jay A; Murgolo, Nicholas; Fridman, Arthur; Johnson, Matthew G; Du, Jiejun; Carmelitano, Patricia; Brown, Michelle L; Paschke, Amanda; De Anda, Carisa

发表日期：2023

文献求助收藏

Participant- and Disease-Related Factors as Independent Predictors of Treatment Outcomes in the RESTORE-IMI 2 Clinical Trial: A Multivariable Regression Analysis

RESTORE-IMI 2 临床试验中参与者和疾病相关因素作为治疗结果的独立预测因子：一项多变量回归分析

期刊:Open Forum Infectious Diseases

影响因子:3.8

doi:10.1093/ofid/ofad225

Martin-Loeches, Ignacio; Shorr, Andrew F; Kollef, Marin H; Du, Jiejun; Losada, Maria C; Paschke, Amanda; DeRyke, C Andrew; Wong, Michael; Jensen, Erin H; Chen, Luke F

发表日期：2023

文献求助收藏

Imipenem/cilastatin/relebactam efficacy, safety and probability of target attainment in adults with hospital-acquired or ventilator-associated bacterial pneumonia among patients with baseline renal impairment, normal renal function, and augmented renal clearance

在基线肾功能受损、肾功能正常和肾清除率增强的成人医院获得性或呼吸机相关性细菌性肺炎患者中，评估亚胺培南/西司他丁/瑞巴坦的疗效、安全性和达标概率。

期刊:JACAntimicrobial Resistance

影响因子:3.7

doi:10.1093/jacamr/dlad011

Roberts, Jason A; Nicolau, David P; Martin-Loeches, Ignacio; Deryke, C Andrew; Losada, Maria C; Du, Jiejun; Patel, Munjal; Rizk, Matthew L; Paschke, Amanda; Chen, Luke F

发表日期：2023

文献求助收藏

Molnupiravir for the treatment of COVID-19 in immunocompromised participants: efficacy, safety, and virology results from the phase 3 randomized, placebo-controlled MOVe-OUT trial

莫努匹拉韦治疗免疫功能低下患者的 COVID-19：来自 3 期随机、安慰剂对照 MOVe-OUT 试验的疗效、安全性和病毒学结果

期刊:Infection

影响因子:3.6

doi:10.1007/s15010-022-01959-9

Johnson, Matthew G; Strizki, Julie M; Brown, Michelle L; Wan, Hong; Shamsuddin, Hala H; Ramgopal, Moti; Florescu, Diana F; Delobel, Pierre; Khaertynova, Ilsiyar; Flores, José F; Fouche, Leon F; Chang, Shan-Chwen; Williams-Diaz, Angela; Du, Jiejun; Grobler, Jay A; Paschke, Amanda; De Anda, Carisa

免疫/内分泌

发表日期：2023

文献求助收藏

A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study)

随机、双盲、多中心试验比较亚胺培南/西司他丁/瑞巴坦与哌拉西林/他唑巴坦治疗成人医院获得性或呼吸机相关性细菌性肺炎的疗效和安全性（RESTORE-IMI 2 研究）

期刊:Clinical Infectious Diseases

影响因子:7.3

doi:10.1093/cid/ciaa803

Titov, Ivan; Wunderink, Richard G; Roquilly, Antoine; Rodríguez Gonzalez, Daniel; David-Wang, Aileen; Boucher, Helen W; Kaye, Keith S; Losada, Maria C; Du, Jiejun; Tipping, Robert; Rizk, Matthew L; Patel, Munjal; Brown, Michelle L; Young, Katherine; Kartsonis, Nicholas A; Butterton, Joan R; Paschke, Amanda; Chen, Luke F

发表日期：2021

文献求助收藏